233 related items for PubMed ID: 15621115
1. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
Ferraresso M, Citterio F, Ghio L, Romagnoli J, Edefonti A, Berardinelli L, Castagneto M.
Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
[Abstract] [Full Text] [Related]
2. Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination.
Ferraresso M, Ghio L, Tirelli S, Pedotti P, Taioli E, Edefonti A, Berardinelli L.
Transplant Proc; 2004 Apr; 36(3):685-6. PubMed ID: 15110630
[Abstract] [Full Text] [Related]
3.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
4. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F.
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[Abstract] [Full Text] [Related]
5.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
6. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F, Scolletta S, Berti L, Maccherini M, Federici D, Bernazzali S, Lisi G, Chiavarelli M.
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[Abstract] [Full Text] [Related]
7. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[Abstract] [Full Text] [Related]
8.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
9. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U, Ullrich S, Roskos M, Misselwitz J.
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[Abstract] [Full Text] [Related]
10. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
Domínguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R.
Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
[Abstract] [Full Text] [Related]
11. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation.
Glanville AR, Morton JM, Aboyoun CL, Plit ML, Malouf MA.
J Heart Lung Transplant; 2004 Oct; 23(10):1170-4. PubMed ID: 15477111
[Abstract] [Full Text] [Related]
12. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[Abstract] [Full Text] [Related]
13. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW.
Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
[Abstract] [Full Text] [Related]
14. Experience with cyclosporine: approaching the therapeutic window for C2 levels in maintenance kidney transplant recipients.
Di Paolo S, Teutonico A, Infante B, Stallone G, Schena A, Grandaliano G, Battaglia M, Di Tonno P, Schena FP.
Transplant Proc; 2004 Mar; 36(2 Suppl):434S-436S. PubMed ID: 15041381
[Abstract] [Full Text] [Related]
15. Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression.
Cardinal H, Barama AA, Fradet V, Lallier M, Lévesque R, St Louis G, Hébert MJ, Girardin C, Pâquet M, Daloze P.
Transplant Proc; 2004 Mar; 36(2 Suppl):448S-450S. PubMed ID: 15041384
[Abstract] [Full Text] [Related]
16. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
Higgins RM, Kanji H, Hernon M, Harrison P, Lam FT, Kashi SH.
Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
[Abstract] [Full Text] [Related]
17. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T.
Transplantation; 2003 Oct 27; 76(8):1236-8. PubMed ID: 14578761
[Abstract] [Full Text] [Related]
18. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
Loichot C, Bentue-Ferrer D, Bernard N, Bonardet A, Boulieu R, Kergueris MF, Paintaud G, Peytavin G, Simon N, Marquet P, Therapeutic Drug Monitoring Group of the French Pharmacological Society.
Fundam Clin Pharmacol; 2006 Feb 27; 20(1):91-6. PubMed ID: 16448399
[Abstract] [Full Text] [Related]
19. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
Transplant Proc; 2007 Dec 27; 39(10):3334-9. PubMed ID: 18089382
[Abstract] [Full Text] [Related]
20. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
Hecking M, Kainz A, Schillinger M, Posch C, Birsan T, Rasoul-Rockenschaub S, Böhmig GA, Schmaldienst S, Watschinger B, Hörl WH, Mühlbacher F, Säemann MD.
Transpl Int; 2008 Mar 27; 21(3):223-33. PubMed ID: 17903183
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
